REPROCELL Receives MSCRF Grant to Accelerate Stem Cell Drug Discovery Capability for Enabling Neuronal Disease Research and Drug Development
25 October 2019
REPROCELL will apply the funding towards the development of stem cell banking for iPSCs and NSCs derived from various neurodegenerative disease patients.
PRESS RELEASE: REPROCELL and NeuCyte enter distribution agreement in North America and Europe
25 September 2019
This new distributorship will grant REPROCELL customers access to NeuCyte's pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons.
PRESS RELEASE: ABLE Biott Bioreactors now available in Europe
22 August 2019
REPROCELL announce the launch of ABLE Biott Bioreactors in Europe. The lab-scale system will allow researchers to culture stem cells in suspension.
REPROCELL Launches cGMP suite in Kawasaki to Accelerate Development of iPSC-derived Glial Progenitors for treatment of CNS disorders
13 May 2019
REPROCELL Inc. today announced that it has established the current good manufacturing practice (cGMP) cell processing suite at Life Innovation Center (LIC) in Tonomachi area in Kawasaki City for production of iPS Cell-derived Glial Progenitors (iGRP) for treatment of CNS disorders.
REPROCELL Announces Research Collaboration with Q Therapeutics and Dr Mahendra Rao
29 November 2017
Learn more about REPROCELL's collaborative research agreement with Q therapeutics to develop new iPS Cell therapies for central nervous system diseases
Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products
22 November 2016
REPROCELL announces an entrustment contract with Healios K.K. for sample testing support of human clinical trials conducted by Healios.
Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development
16 November 2016
Today, REPROCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. for the development of a 3D model system derived from human iPS cells.
A Joint Development with the National Cancer Center Information Regarding the Sale of “ReproHP Medium,” a Culture Fluid for Human Primary Liver Cells with High Levels of Functionality
16 November 2015
“ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the National Cancer Center, is set to go on sale in December this year.
Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells
04 November 2015
REPROCELL like to inform you that a patent application concerning an amplification method of hematopoietic stem cells which we applied for jointly with Nissan Chemical Industries, Ltd., has passed screening in the United States.
The REPROCELL Group announces publication of a paper on its state-of-the-art RNA Reprogramming technology in Human Gene Therapy, an international journal
14 October 2015
Group affiliate Stemgent Inc. (US) is pleased to announce the publication of a paper on state-of-the-art iPS cell production technology, entitled “RNA Reprogramming,” that was written collaboratively with the Whitehead Institute (USA).
REPROCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells
08 September 2015
REPROCELL is pleased to announce that our company has entered into an exclusive licensing agreement with Keio University regarding myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells.
Announcement: New High Performance Cryopreservation Solution – ReproCryo DMSO Free
26 August 2015
Read more about how REPROCELL's new high-performance cryopreservation solution ReproCryo (DMSO free) is advancing the field of regenerative medicine.
Announcement of Award for Prototype Development of Large-Scale Production on Human-iPSC derived Cardiomyocytes
14 August 2015
REPROCELL would like to announce that on August 3rd, 2015, one of our projects, “Prototype Development of a Large- Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells” (hereafter, “the project”) was selected to receive a Subsidy for Collaborative Projects to Advance the Creation of an Innovative Manufacturing Industry (FY 2015-2016).
Diseased neurons derived from iPS cells of Alzheimer’s disease patients Initiation of sales of “ReproNeuro AD-patient”
29 July 2015
REPROCELL is pleased to announce that on August 10th our company began sales of “ReproNeuro AD-patient,” diseased neurons made from iPS cells derived from Alzheimer’s disease patients.
Announcement: sales commencement of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells
21 July 2015
This is a notice that we will on August 3rd 2015 commence sales of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells.
Announcement of Award for Prototype Development of a Liver Cell Kit
01 July 2015
REPROCELL is pleased to announce that one of our projects, “Prototype Development of a Liver Cell Kit Derived From Functional Human Induced Pluripotent Stem (iPS) Cells for Applications in Drug Discovery” has been selected as a recipient of Grant for Manufacturing, Commerce, and Service Innovation additionally allocated for FY 2014-2015.
Stemgent, a REPROCELL Group Company Announces a New High Performance Self-replicative RNA Reprogramming Kit
30 June 2015
Read REPROCELL Group company Stemgent inc.'s announcement of a New High Performance Self-replicative RNA Reprogramming Kit: Stemgent StemRNA™-SR
REPROCELL Concludes the License Agreement with Keio University for the Exclusive Sale of Disease (Hypertrophic Cardiomyopathy) Type Myocardial Cells Derived from iPS Cells
04 June 2015
Read about REPROCELLS exclusive distribution and licensing agreement with Keio University regarding myocardial cells originating from disease type iPS Cells
REPROCELL Acquires the iPS Cell Business Unit of Stemgent, Inc. (USA)
09 September 2014
REPROCELL announced that it will acquire the iPS Cell Business Unit of Stemgent, Inc. allowing REPROCELL to expand the product lineup of its iPSC Business